ArticleJournal of pain research2026
In vitro Effects of Gadoteric Acid and Iobitridol Toxicity and Platelet-Rich Plasma-Mediated Protection in Human Annulus Fibrosus and Nucleus Pulposus Cells.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study Design: Laboratory study. Objective: Intervertebral disc (IVD) degeneration, a major cause of chronic low back pain characterized by reduced viability of Annulus Fibrosus (AF) and Nucleus Pulposus (AP) cells, can be treated with platelet-rich plasma (PRP), although confirming needle placement with radiopaque contrast, commonly used for this purpose, may negatively affect cellular viability. The objective of this study was to evaluate the cytotoxic effects of gadoteric acid (GA) and iobitridol (IB), commonly used contrast agents, and the protective potential of two PRP formulations: standard PRP (sPRP) and balanced protein-concentrate plasma (BPCP). Methods: AF and NP cells were exposed to varying concentrations of GA and IB (0-100% v/v) for 1 and 2 hours, with or without 10% (v/v) PRP supplementation. PRP from five donors was pooled (n=1), and experiments were performed in technical triplicates (n=3). Cell viability was measured by luminescence-based RealTimeGlo MT assay. The difference among the groups was analysed and multivariable regression was performed. Results: Both contrast agents appeared to exert dose- and time-dependent cytotoxicity. PRP was associated with improved cell viability, with BPCP appearing to provide increased viability under exposure to higher contrast concentrations. Multivariate regression analyses indicated that contrast concentration, exposure time, and PRP type were key determinants of cell viability. Conclusion: These findings appear to underline the importance of minimizing contrast agent exposure during IVD procedures and suggest that PRP formulations, particularly BPCP, may provide improved cell viability against contrast-induced cytotoxicity. Future in vitro and in vivo studies will be needed to further validate these results and assess their clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.